Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Explore available award and grant opportunities for fellows-in-training.
Make a choice that matters
The best care starts with the best information. See videos to help answer your questions.
The ACR is accepting applications for mini curriculums, which are educational activities or curriculums to enhance the ACR Core Curriculum Outline.
Rheumatology advocacy involves several branches of government and various agencies. ACR advocates to Congress, federal agencies, and others by writing or signing on to various policy letters.
ACR Joins AMA Letter Asking Congress to Address Surprise Billing Separately from COVID-19 Recovery Legislation - 7/29/2020
ACR Joins Coalition Letter Asking Congress to Include the Resident Physician Shortage Reduction Act (HR 1763/S 348) in Next COVID-19 Package - 7/9/2020
ACR Joins Coalition Letter Urging CMS to Follow Through with E/M Increases, Documentation Improvements - 6/30/2020
ACR Writes to Thank House and Senate Leaders for Introducing the Workforce Resilience Act (HR 6788/S 3599) - 6/15/2020
ACR Joins AMA to Ask House and Senate Leaders for Liability Protections for Healthcare Providers in Next COVID-19 Legislative Package - 6/9/2020
ACR Signs Coalition letter to CMS Asking for Guardrails on the Use of Step Therapy - 5/29/2020
Coalition Open Letter to All Health Plans Calling for Suspension of Prior Authorization - 5/18/2020
ACR Signs Coalition letter Requesting Funding for Pediatric Subspecialty Loan Repayment Program in COVID Relief Legislation - 5/13/2020
ACR Comments on CMS Interim Final Rule on Policies Related to COVID-19 Public Health Emergency - 4/27/2020
ACR Signs Coalition Letter to Congress to Restrict Step Therapy Use During COVID-19 - 4/20/2020
ACR Signs Coalition Letter Requesting Inclusion of Support for Physician Practices in any Economic Stimulus Package - 3/25/2020
Joint Statement on Hydroxychloroquine Access During COVID-19 Crisis - 3/23/2020
32 Veterans Service Organizations Join ACR to Urge Congress to Dedicate DoD Funding to Researching Arthritis in the Military - 3/12/2020
ACR Signs Coalition Letter Requesting Labor-HHS Report Language on Researching Musculoskeletal Disease in Intersectional Populations - 3/11/2020
ACR Comments to Congress Supporting HR-5741 - Strengthening Innovation in Medicare and Medicaid Act - 3/11/2020
More Than 140 Patient, Provider, Retiree Organizations Urge Congress to Erect Safeguards Around Medicare, Medicaid Demonstration Projects - 3/10/2020
ACR Signs Coalition Letter to Congress to Support Safe Step Act - 3/6/2020
ACR Comments on 2021 HHS Notice of Benefit and Payment Parameters - 3/2/2020
ACR Signs Coalition Letter to CMS Supporting E/M Valuation and Complexity Code Policies - 2/10/2020
ACR Comments to CMS on CY2020 Physician Fee Schedule and Quality Payment Program Final Rule - 12/31/19
Coalition Letter to Congress Supporting CMS E/M Updates - 11/21/19
Coalition Letter to House on Surprise Billing - 10/16/19
Coalition Letter to Senate on Surprise Billing - 10/16/19
Coalition Letter to Congress Supporting Pediatric Specialty Workforce, S.2443 - 10/24/19
ACR Comments on Physician Fee Schedule and Quality Payment Program 2020 Proposed Rule - 9/16/19
Coalition Letter to Congress Urging Prior Authorization Reform, H.R. 3107 - 9/9/19
ACR Comments on Electronic Prior Authorization Part D Proposed Rule - 8/16/19
ACR Comments on Senate Finance Drug Pricing Proposals - 7/24/19
ACR Support for H.R. 2373 Prescription Pricing for the People Act - 7/9/19
ACR Feedback on Draft Medicare Part D Legislation - 6/6/19
Coalition Letter on Needed MACRA improvements - 6/3/19
ACR Comments to FDA on Nonproprietary Naming of Biological Products - 5/7/19
ACR Comments on Safe Harbor Rebate Rule - 4/8/19
Coalition Letter on Step Therapy - 4/8/19
ACR Comments on Pain Management Best Practices - 4/1/19
ACR Comments on Notice of Benefit and Payment Parameters for 2020 Proposed Rule - 2/19/19
ACR Comments on Part D Medicare Advantage Proposed Rule - 1/22/19
ACR Comments on Healthy People 2030 Objectives - 1/17/19
ACR Comments on 2019 Medicare Physician Fee Schedule Final Rule - 12/31/18
ACR Comments on Medicare Part B Drugs International Pricing Index Model - 12/27/18
Coalition Letter on Medicare Advantage Step Therapy - 10/1/18
ACR Response to CMS on Competitive Acquisition Program Request for Information - 9/24/18
ACR Letter to CMS on 2019 Physician Fee Schedule and Quality Payment Program - 9/6/18
ACR Comments in FDA Public Meeting on Biosimilars - 9/5/18
Stakeholder Letter to CMS on E/M Proposals in 2019 Medicare Physician Fee Schedule - 8/28/18
ACR Letter to HHS on Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs - 7/13/18
Coalition Letter to CMS on Shortening the 2018 MIPS Reporting Period - 4/27/18
ACR Letter to CMS on Short-Term Limited Duration Insurance - 4/23/18
Coalition Letter to CMS on Short-Term Limited Duration Insurance - 4/23/18
Coalition Letter to CMS on Prior Authorization under Medicare Advantage and the Patients Over Paperwork Initiative - 4/4/18
Physician Group Letter to HHS on Drug Pricing Proposals - 3/14/18
ACR Comments to CMS on Clinical Laboratory Improvement Amendments - 3/12/18
ACR Comments to Department of Labor on Association Health Plan Proposed Rule - 3/5/18
ACR Response to HHS Request for Information on Promoting Healthcare Choice and Competition - 1/25/18
ACR Letter to FDA: Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases - 1/19/18
Coalition Letter to House on MIPS Adjustment to Part B Drugs - 1/18/18
Coalition Letter to Senate on MIPS Adjustment to Part B Drugs - 1/18/18
ACR Letter to CMS on Medicare Advantage Proposed Rule - 1/16/18